Asymptomatic COVID–19 cancer patients incidentally discovered during F18-FDG PET/CT monitoring

Piciu, Andra; Manole, Simona; Piciu, Doina; Dreve, Teodora; Roman, Andrei

doi:10.15386/mpr-1776

Cited by 2 publications

(9 citation statements)

References 19 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients had a mean age of 62.25 ± 14.85 years (male: 67.71 ± 12.00; female: 56.79 ± 15.81). Of the total patients, 83.33% (25/30) were enrolled from Europe, including Italy, France, Spain, Romania, and Portugal [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ]; 13.33% (4/30) from North America (USA and Canada) [ 25 , 26 , 27 , 28 ]; and 3.33% (1/30) from Iran [ 29 ]. Of the total, 83.33% (25/30) were oncological patients who received [ 18 F]FDG PET/CT under clinical indications for staging, restaging, follow-up, and for the evaluation of therapeutic response [ 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 ].…”

Section: Resultsmentioning

confidence: 99%

“…Of the total patients, 83.33% (25/30) were enrolled from Europe, including Italy, France, Spain, Romania, and Portugal [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ]; 13.33% (4/30) from North America (USA and Canada) [ 25 , 26 , 27 , 28 ]; and 3.33% (1/30) from Iran [ 29 ]. Of the total, 83.33% (25/30) were oncological patients who received [ 18 F]FDG PET/CT under clinical indications for staging, restaging, follow-up, and for the evaluation of therapeutic response [ 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 ]. The other five patients (P9, 18, 24, 28, and 30) underwent [ 18 F]FDG PET/CT for the detection of non-oncological disease or for the evaluation of clinically suspicious malignant disease [ 15 , 17 , 23 , 26 , 29 ], of which one patient (P28) was diagnosed with lung adenocarcinoma [ 26 ].…”

Section: Resultsmentioning

confidence: 99%

“…[ 18 F]FDG-avid extrapulmonary lesions were found in 56.66% (17/30) of total patients. Hypermetabolic activities were separately detected in non-thoracic lymph node (LN) (n = 6: P1, 8, 14, 16, 19, and 25) [ 12 , 13 , 15 , 18 , 22 ], primary carcinoma alone (n = 5: P2, 17, 20, 22, and 29) [ 19 , 22 , 23 , 24 ], inflammatory tissues (n = 2: P3 and 30) [ 17 , 25 ], metastatic site (n = 2: P4 and 13) [ 12 , 27 ], primary carcinoma mixed metastatic site (n = 1: P7) [ 14 ], and primary carcinoma mixed non-thoracic lymph node (n = 1: P6) [ 28 ].…”

Section: Resultsmentioning

confidence: 99%

“…Of the total patients, 90% (27/30) demonstrated [ 18 F]FDG-avid lung lesions, (except for P11 [ 15 ], 21 [ 20 ], and 24 [ 27 ].) Patients numbered P11 and P21 demonstrated different oncological diseases with no [ 18 F]FDG-avid lung lesion and no above pulmonary alternation, respectively [ 15 , 22 ]. P24 was a non-oncological patient with unknown anosmia, and the abnormal [ 18 F]FDG uptake was only detected on her right hilar LN [ 27 ].…”

Section: Resultsmentioning

confidence: 99%

“…All patients were asymptomatic for COVID-19 at time of [ 18 F]FDG PET/CT imaging. [12,13,15,18,22], primary carcinoma alone (n = 5: P2, 17, 20, 22, and 29) [19,[22][23][24], inflammatory tissues (n = 2: P3 and 30) [17,25], metastatic site (n = 2: P4 and 13) [12,27], primary carcinoma mixed metastatic site (n = 1: P7) [14], and primary carcinoma mixed non-thoracic lymph node (n = 1: P6) [28].…”

Section: Selection Of Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Pulmonary Findings of [18F]FDG PET/CT Images on Asymptomatic COVID-19 Patients

Chang

Chan

et al. 2021

Pathogens

View full text Add to dashboard Cite

During the coronavirus disease 2019 (COVID-19) pandemic, several case studies demonstrated that many asymptomatic patients with COVID-19 underwent fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) examination for various indications. However, there is a lack of literature to characterize the pattern of [18F]FDG PET/CT imaging on asymptomatic COVID-19 patients. Therefore, a systematic review to analyze the pulmonary findings of [18F]FDG PET/CT on asymptomatic COVID-19 patients was conducted. This systematic review was performed under the guidelines of PRISMA. PubMed, Medline, and Web of Science were used to search for articles for this review. Articles with the key words: “asymptomatic”, “COVID-19”, “[18F]FDG PET/CT”, and “nuclear medicine” were searched for from 1 January 2020 to 20 May 2021. Thirty asymptomatic patients with COVID-19 were included in the eighteen articles. These patients had a mean age of 62.25 ± 14.85 years (male: 67.71 ± 12.00; female: 56.79 ± 15.81). [18F]FDG-avid lung lesions were found in 93.33% (28/30) of total patients. The major lesion was [18F]FDG-avid multiple ground-glass opacities (GGOs) in the peripheral or subpleural region in bilateral lungs, followed by the consolidation. The intensity of [18F]FDG uptake in multiple GGOs was 5.605 ± 2.914 (range from 2 to 12) for maximal standardized uptake value (SUVmax). [18F]FDG-avid thoracic lymph nodes (LN) were observed in 40% (12/40) of the patients. They mostly appeared in both mediastinal and hilar regions with an SUVmax of 5.8 ± 2.93 (range from 2.5 to 9.6). The [18F]FDG uptake was observed in multiple GGOs, as well as in the mediastinal and hilar LNs. These are common patterns in PET/CT of asymptomatic patients with COVID-19.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Selection Of Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Pulmonary Findings of [18F]FDG PET/CT Images on Asymptomatic COVID-19 Patients

Chang

Chan

et al. 2021

Pathogens

View full text Add to dashboard Cite

show abstract

The SARS-COV-2 Seroprevalence among Oncology Patients

Kgatle

Das

Lawal

et al. 2023

JCM

View full text Add to dashboard Cite

Patients with cancer are presumed to be vulnerable to an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe clinical outcomes due to the immunocompromised state mediated by their underlying malignancies and therapy. The aim of this study was to estimate the SARS-CoV-2 seroprevalence, following second to fourth waves in solid tumour patients attending the Steve Biko Academic Hospital (SBAH) for diagnosis and treatment of cancer. We used the single-prick COVID-19 IgG/IgM Rapid Test Cassettes to detect SARS-CoV-2 IgG/IgM antibodies in 760 patients with solid tumours who were asymptomatic and who had never tested positive for coronavirus disease 2019 (COVID-19). Out of the 760 patients, 277 were male (36.4%), 483 were female (63.6%), and the mean age was 55 years (range 18–92). The estimated total seroprevalence was 33.2%. The seroprevalence status of the COVID-19 IgG/IgM antibodies rose significantly from the second wave (11.3%) to the third (67.38%) and then the fourth (69.81%) waves with roughly similar counts. A significant number of the seropositive patients were asymptomatic to COVID-19 (96%). There was a higher rate of seropositivity in cancer patients with hypertension (p < 0.05). Patients with breast, gynaecologic, and prostate cancers exhibited increased SARS-CoV-2 seropositivity. Although oncology patients may be susceptible to SARS-CoV-2 infection, our data indicate that these patients remained asymptomatic throughout various waves with an overall COVID-19 IgG/IgM antibody seropositivity of 33.16%, suggesting no risk of severe or fatal cases of COVID-19.

show abstract

Asymptomatic COVID–19 cancer patients incidentally discovered during F18-FDG PET/CT monitoring

Cited by 2 publications

References 19 publications

Pulmonary Findings of [18F]FDG PET/CT Images on Asymptomatic COVID-19 Patients

Pulmonary Findings of [18F]FDG PET/CT Images on Asymptomatic COVID-19 Patients

The SARS-COV-2 Seroprevalence among Oncology Patients

Contact Info

Product

Resources

About